Immunohistochemistry Biomarker TP53 Expression Predicts the Survival of Thymomas

Overview

Journal Gland Surg

Publisher AME Publishing Company

Specialty Endocrinology

Date 2020 May 19

PMID 32420253

Citations 1

Authors

Dongliang Bian

Liting Zhao

Xuelin Zhang

Fanzhen Lv

Zhenghong Zhu

Hui Qiu

Huibiao Zhang

Affiliations

Soon will be listed here.

Abstract

Background: Thymomas are rare malignancies. Thymectomy is the optimal therapy which could prolong the survival of patients. However, prognostic factors of thymomas are not clear.

Methods: Thymomas patients were enrolled from 2001 to 2016. Clinical and pathological prognostic factors of thymomas were evaluated by univariate and multivariate analyses.

Results: A total number of 98 patients was eligible for this study. All patients were received complete resection (CR). Diagnostic age [elder than the median 60 . younger than 60, hazard ratio (HR) =2.325, P=0.027], Masaoka stage (III I, HR =10.756, P<0.001; IV . I, HR =6.558, P=0.014), and diabetes mellitus (DM) (with without, HR =0.142, P=0.004) were independent prognostic factors for overall survival (OS). Immunohistochemistry (IHC) biomarker TP53 expression also influenced OS significantly (positive negative, HR =5.157, P=0.018). Furthermore, age (elder than 60 . younger than 60, HR =2.980, P=0.022) was independent prognostic factors for recurrence free survival (RFS).

Conclusions: We found that diagnostic age, clinical stages, DM, TP53 expression in IHC, and quality perioperative nursing are prognostic factors in thymomas.

Citing Articles

Metformin as a promising target for DPP4 expression: computational modeling and experimental validation.

El-Arabey A, Zhang H, Abdalla M, Al-Shouli S, Alkhalil S, Liu Y Med Oncol. 2023; 40(10):277.

PMID: 37624423 PMC: 10457412. DOI: 10.1007/s12032-023-02140-4.

References

Bian D, Ge T, Song N, Zhang P, Zhang H, Fei K . The secondary surgery provides significant benefits to recurrent thymoma: a retrospective analysis based on Surveillance, Epidemiology and End Results database. Transl Cancer Res. 2022; 8(3):840-847. PMC: 8798746. DOI: 10.21037/tcr.2019.05.09. View

Schmitt J, Loehrer Sr P . The role of chemotherapy in advanced thymoma. J Thorac Oncol. 2010; 5(10 Suppl 4):S357-60. DOI: 10.1097/JTO.0b013e3181f21129. View

Jackson M, Palma D, Camidge D, Jones B, Robin T, Sher D . The Impact of Postoperative Radiotherapy for Thymoma and Thymic Carcinoma. J Thorac Oncol. 2017; 12(4):734-744. DOI: 10.1016/j.jtho.2017.01.002. View

Castillo-Quan J, Blackwell T . Metformin: Restraining Nucleocytoplasmic Shuttling to Fight Cancer and Aging. Cell. 2016; 167(7):1670-1671. DOI: 10.1016/j.cell.2016.11.058. View

Fu H, Gu Z, Fang W, Fu J, Shen Y, Han Y . Long-Term Survival After Surgical Treatment of Thymic Carcinoma: A Retrospective Analysis from the Chinese Alliance for Research of Thymoma Database. Ann Surg Oncol. 2015; 23(2):619-25. DOI: 10.1245/s10434-015-4825-4. View

Zucali P, De Pas T, Palmieri G, Favaretto A, Chella A, Tiseo M . Phase II Study of Everolimus in Patients With Thymoma and Thymic Carcinoma Previously Treated With Cisplatin-Based Chemotherapy. J Clin Oncol. 2017; 36(4):342-349. DOI: 10.1200/JCO.2017.74.4078. View

Muller P, Vousden K . p53 mutations in cancer. Nat Cell Biol. 2012; 15(1):2-8. DOI: 10.1038/ncb2641. View

. Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data. Lancet. 2014; 383(9928):1561-71. PMC: 4022989. DOI: 10.1016/S0140-6736(13)62159-5. View

Filosso P, Evangelista A, Ruffini E, Rendina E, Margaritora S, Novellis P . Does myasthenia gravis influence overall survival and cumulative incidence of recurrence in thymoma patients? A Retrospective clinicopathological multicentre analysis on 797 patients. Lung Cancer. 2015; 88(3):338-43. DOI: 10.1016/j.lungcan.2015.03.007. View

10.

Govindarajan R, Ratnasinghe L, Simmons D, Siegel E, Midathada M, Kim L . Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes. J Clin Oncol. 2007; 25(12):1476-81. DOI: 10.1200/JCO.2006.07.2777. View

11.

Agatsuma H, Yoshida K, Yoshino I, Okumura M, Higashiyama M, Suzuki K . Video-Assisted Thoracic Surgery Thymectomy Versus Sternotomy Thymectomy in Patients With Thymoma. Ann Thorac Surg. 2017; 104(3):1047-1053. DOI: 10.1016/j.athoracsur.2017.03.054. View

12.

Mengoli M, Longo L, Varini S, Rossi G, Lococo F . Invasive Medullary Type A Thymoma With Recurrent Distant Metastases. Ann Thorac Surg. 2017; 103(5):e423-e425. DOI: 10.1016/j.athoracsur.2016.11.018. View

13.

Thomas A, Rajan A, Berman A, Tomita Y, Brzezniak C, Lee M . Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial. Lancet Oncol. 2015; 16(2):177-86. PMC: 4401497. DOI: 10.1016/S1470-2045(14)71181-7. View

14.

Bian D, Qi M, Hu J, Ning Y, Zhou F, Fei K . The comparison of predictive factors regarding prognoses and invasion of thymic neuroendocrine tumors preoperatively and postoperatively. J Thorac Dis. 2018; 10(3):1657-1669. PMC: 5906298. DOI: 10.21037/jtd.2018.02.82. View

15.

Bian D, Zhou F, Yang W, Zhang K, Chen L, Jiang G . Thymoma size significantly affects the survival, metastasis and effectiveness of adjuvant therapies: a population based study. Oncotarget. 2018; 9(15):12273-12283. PMC: 5844745. DOI: 10.18632/oncotarget.24315. View

16.

Imbimbo M, Ottaviano M, Vitali M, Fabbri A, Leuzzi G, Fiore M . Best practices for the management of thymic epithelial tumors: A position paper by the Italian collaborative group for ThYmic MalignanciEs (TYME). Cancer Treat Rev. 2018; 71:76-87. DOI: 10.1016/j.ctrv.2018.10.001. View

17.

Moreira A, Won H, McMillan R, Huang J, Riely G, Ladanyi M . Massively parallel sequencing identifies recurrent mutations in TP53 in thymic carcinoma associated with poor prognosis. J Thorac Oncol. 2014; 10(2):373-80. DOI: 10.1097/JTO.0000000000000397. View

18.

Radovich M, Pickering C, Felau I, Ha G, Zhang H, Jo H . The Integrated Genomic Landscape of Thymic Epithelial Tumors. Cancer Cell. 2018; 33(2):244-258.e10. PMC: 5994906. DOI: 10.1016/j.ccell.2018.01.003. View

19.

Zou B, Xu Y, Li T, Li W, Tang B, Zhou L . A multicenter retrospective analysis of survival outcome following postoperative chemoradiotherapy in non-small-cell lung cancer patients with N2 nodal disease. Int J Radiat Oncol Biol Phys. 2009; 77(2):321-8. DOI: 10.1016/j.ijrobp.2009.05.044. View

20.

Hatlen P, Gronberg B, Langhammer A, Carlsen S, Amundsen T . Prolonged survival in patients with lung cancer with diabetes mellitus. J Thorac Oncol. 2011; 6(11):1810-7. DOI: 10.1097/JTO.0b013e31822a75be. View